Hemab Therapeutics Holdings, Inc. (COAG)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
39.51 USD
+1.48
(3.892%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 41.00 +1.49 (3.771%) ⇧ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:57 a.m. EDT
The immediate outlook is neutral due to a lack of statistical data to confirm short-term momentum, despite the stock trading near its 52-week high. While the recent price action shows volatility with a sharp recovery from mid-June lows, the absence of a reliable forecasting model prevents assigning a bullish edge. Fundamentally, the company presents a classic biotech profile: a massive balance sheet cushion with negligible debt and strong liquidity, yet it is burdened by significant operating cash outflows and negative earnings. This financial structure supports survival but offers no immediate profit visibility. The recent news of a successful IPO and positive analyst initiation suggests the market is pricing in future pipeline potential rather than current performance. However, without a proven track record of revenue growth or profitability, the investment case relies entirely on the success of upcoming clinical trials, making it a speculative hold rather than a conviction buy at these levels. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.658 |
| Market Cap | 1,845,330,560 |
| Forward P/E | -15.72 |
| Website | https://www.hemab.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11852944 |
| Address1 | 101 Main Street |
| Address2 | Suite 1220 |
| All Time High | 38.87 |
| All Time Low | 23.0 |
| Ask | 48.96 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 314,460 |
| Average Daily Volume3 Month | 351,156 |
| Average Volume | 351,156 |
| Average Volume10Days | 314,460 |
| Bid | 29.92 |
| Bid Size | 2 |
| Book Value | -209.956 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.51 |
| Current Ratio | 12.846 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 42.03 |
| Day Low | 37.99 |
| Debt To Equity | 0.658 |
| Display Name | Hemab Therapeutics |
| Earnings Timestamp | 1,779,366,600 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda | -76,869,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -26.578 |
| Enterprise Value | 2,043,030,784 |
| Eps Current Year | -3.06333 |
| Eps Forward | -2.51333 |
| Eps Trailing Twelve Months | -10.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.445 |
| Fifty Day Average Change | 11.064999 |
| Fifty Day Average Change Percent | 0.38899627 |
| Fifty Two Week Change Percent | 11.852943 |
| Fifty Two Week High | 42.03 |
| Fifty Two Week High Change | -2.5200005 |
| Fifty Two Week High Change Percent | -0.059957188 |
| Fifty Two Week Low | 23.0 |
| Fifty Two Week Low Change | 16.509998 |
| Fifty Two Week Low Change Percent | 0.717826 |
| Fifty Two Week Range | 23.0 - 42.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,777,642,200,000 |
| Float Shares | 23,742,228 |
| Forward Eps | -2.51333 |
| Forward P E | -15.72018 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10781 |
| Held Percent Institutions | 0.65888 |
| Implied Shares Outstanding | 46,705,410 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-05-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. |
| Long Name | Hemab Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 1,845,330,560 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1994300807 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -71,294,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,779,242,593 |
| Number Of Analyst Opinions | 5 |
| Open | 38.39 |
| Operating Cashflow | -70,026,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | (617) 553-3952 |
| Post Market Change | 1.4900017 |
| Post Market Change Percent | 3.7712016 |
| Post Market Price | 41.0 |
| Post Market Time | 1,783,987,006 |
| Previous Close | 38.03 |
| Price Eps Current Year | -12.897729 |
| Price Hint | 2 |
| Price To Book | -0.18818228 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.507 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 1.48 |
| Regular Market Change Percent | 3.89166 |
| Regular Market Day High | 42.03 |
| Regular Market Day Low | 37.99 |
| Regular Market Day Range | 37.99 - 42.03 |
| Regular Market Open | 38.39 |
| Regular Market Previous Close | 38.03 |
| Regular Market Price | 39.51 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 365,842 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 46,705,410 |
| Shares Percent Shares Out | 0.0367 |
| Shares Short | 1,354,937 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,026,514 |
| Short Name | Hemab Therapeutics Holdings, In |
| Short Ratio | 5.74 |
| Source Interval | 15 |
| State | MA |
| Symbol | COAG |
| Target High Price | 50.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 41.4 |
| Target Median Price | 40.0 |
| Total Cash | 163,531,008 |
| Total Cash Per Share | 3.501 |
| Total Debt | 1,063,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.445 |
| Two Hundred Day Average Change | 11.064999 |
| Two Hundred Day Average Change Percent | 0.38899627 |
| Type Disp | Equity |
| Volume | 365,842 |
| Website | https://www.hemab.com |
| Zip | 2,142 |